Adaptive Biotechnologies Corp (ADPT) financials
Adaptive Biotechnologies revenue and earnings by year
Adaptive Biotechnologies's revenue was $277 million in the fiscal year to December 31, 2025, up 54.8% from the year before. Net income was -$59.5 million, -21.5% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 28.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 277 | 179 | 170 | 185 | 154 | 98 | 85 | 56 | 38 |
| Revenue growth | 54.8% | 5.1% | -8.1% | 20.1% | 56.9% | 15.6% | 52.8% | 44.8% | — |
| Gross profit | 206 | 107 | 95 | 127 | 105 | 76 | 63 | 36 | 23 |
| Gross margin | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating income | -57 | -163 | -227 | -200 | -209 | -153 | -78 | -50 | -44 |
| Operating margin | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.1% | -89.4% | -115.7% |
| Net income | -59 | -159 | -225 | -200 | -207 | -146 | -69 | -46 | -43 |
| Net margin | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.6% | -83.4% | -111.4% |
| Diluted EPS | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.10 | — | -$3.68 | — |
| Free cash flow | -49 | -99 | -167 | -200 | -254 | -168 | 194 | -39 | -37 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ADPT in Markets.
See also: ADPT returns
No forecast, no recommendation. This page describes Adaptive Biotechnologies Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.